Source comparison
Peptides for GERD Compared: Mechanism Comparison
BPC-157 VEGF receptor upregulation, collagen synthesis, angiogenesis in damaged mucosa Esophageal erosions, Barrett's metaplasia, hiatal hernia complications 48-72 hours (tissue repair visible in animal models) Preclinical. Extensive animal data, no Phase 3 hu
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF receptor upregulation, collagen synthesis, angiogenesis in damaged mucosa
- Esophageal erosions, Barrett's metaplasia, hiatal hernia complications
- 48-72 hours (tissue repair visible in animal models)
- Preclinical. Extensive animal data, no Phase 3 human trials
- 200-500 mcg SC daily, reconstituted from lyophilized powder
- Best for active mucosal damage requiring accelerated healing. Does not address mechanical reflux causes
- Tesamorelin
- GHRH analogue reducing visceral adiposity, decreasing intra-abdominal pressure on LES
- Mechanical reflux secondary to central obesity, metabolic syndrome
- 12-16 weeks (measurable visceral fat reduction)
- FDA-approved for lipodystrophy; GERD benefit is observational
- 2 mg SC daily, consistent timing required
- Best for reflux driven by abdominal fat distribution. No direct mucosal healing effect
- PPI (Comparison)
- Proton pump inhibition reducing gastric acid secretion
- Acid-mediated mucosal injury
- 24-48 hours (symptom relief)
- Standard of care
- 20-40 mg oral daily
- Suppresses symptoms but does not repair existing damage or address anatomical contributors